Skip to main content

Table 1 Characteristics of pregnant women infected with HIV at CAISM/UNICAMP from 2000 to 2015

From: Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study

Characteristics

n

Median (%)

Age (years)

793

28 (13–46)

Parity

793

1 (0–9)

Schooling years (n = 769)

  < 8

468

60.9

 8–11 yrs.

248

32.2

  > 12

39

5.1

 No schooling

14

1.8

Ethnicity: White

485

61.2

HIV diagnosis (n = 789)

 Prior to pregnancy

489

62.5

 During pregnancy

294

37.5

In use of ART at conception (n = 787)

217

27.6

In use of Efavirenz at conception (n = 793)

81

10.2

Planned pregnancy (n = 382)

98

25.7

Heterosexual transmission (n = 408)

380

93.1

Opportunistic disease during pregnancy (n = 785)

32

4.1

First CD4 median (cel/ml)

734

444 (3–1915)

Peripartum CD4 median (cel/ml)

175

552 (5–2164)

Median time of ART use (days)

410

152.5 (4–292)

Peripartum Viral Load < 50 (copies/ml) (n = 732)

432

58.9

CDC classification (n = 758)

 1

227

29.9

 2

391

51.6

 3

140

18.5

Coinfections during pregnancy (n = 787)

667

84.8

Obstetrics complications (n = 792)

417

52.7

ART adherence during prenatal care

649

84.3

Changed ART (n = 776)

149

19.2

Premature rupture of membranes (n = 773)

121

15.7

Labor (n = 447)

188

42.1

Intravenous AZT (n = 775)

735

94.8

Antiretroviral regimens during pregnancy (n = 793)

 None

15

1.9

 Monotherapy with AZT

23

2.9

 NRTI + NRTI

11

1.4

 NRTI + NRTI + NVP

138

17

 NRTI + NRTI + NFV

135

17

 NRTI + NRTI + LPV/R

428

54

 Regimens with other PI

40

5

 NRTI + NRTI + EFV

3

0.4

TOTAL

793

100

  1. ART antiretroviral therapy, AZT zidovudine, NRTI nucleos(t)ide reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitor, NVP nevirapine, EFV efavirenz, PI protease inhibitor, NFV nelfinavir, LPV lopinavir, R ritonavir, CDC Centers for Disease Control and Prevention